These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 823117)

  • 21. Cholera toxoid boosts serum Escherichia coli antitoxin in humans.
    Nalin DR; al-Mahmud A; Curlin G; Ahmed A; Peterson J
    Infect Immun; 1974 Oct; 10(4):747-9. PubMed ID: 4609909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intestinal immunization with soluble bacterial antigens: the example of cholera toxoid.
    Pierce NF
    Ciba Found Symp; 1976; (42):129-47. PubMed ID: 1086763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Properties of C1. perfringens toxoids obtained from purified toxins].
    Dmitrieva LN; Shemanova GF; Vlasova EV; Akhundova KA
    Zh Mikrobiol Epidemiol Immunobiol; 1977 Apr; (4):110-4. PubMed ID: 868405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of purified Habu snake-venom toxoid in guinea pigs and monkeys with special reference to HR1 component.
    Sadahiro S; Omori-Satoh T; Yamauchi K; Kondo S; Ishida S; Murata R
    Jpn J Med Sci Biol; 1981 Aug; 34(4):213-30. PubMed ID: 6798252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The standardization of Cl. perfringens antigens and antisera.
    Jansen BC
    Dev Biol Stand; 1976; 32():35-44. PubMed ID: 187510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune response of the intestinal mucosa to cholera toxoid.
    Pierce NF; Sack RB
    J Infect Dis; 1977 Aug; 136 Suppl():S113-7. PubMed ID: 894085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immunochemical and biochemical characteristics of a preventive preparation against cholera, cholerogen-toxoid].
    Dzhaparidze MN; Sumarokov AA; Martens LA; Egorova VD; Karaeva LT
    Zh Mikrobiol Epidemiol Immunobiol; 1976 May; (5):32-7. PubMed ID: 941601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experiments with cholera toxin detoxified with glutaraldehyde.
    Saletti M; Ricci A
    Bull World Health Organ; 1974; 51(6):633-9. PubMed ID: 4219758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of anti-lipopolysaccharide antibodies to Vibrio cholerae O1 and O139 using a novel microtiter limulus amebocyte lysate (LAL) assay.
    Chang HS; Sack DA
    Clin Chim Acta; 2001 Oct; 312(1-2):49-54. PubMed ID: 11580909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral immunization of dogs with purified cholera toxin, crude cholera toxin, or B subunit: evidence for synergistic protection by antitoxic and antibacterial mechanisms.
    Pierce NF; Cray WC; Sacci JB
    Infect Immun; 1982 Aug; 37(2):687-94. PubMed ID: 6889574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunity in experimental cholera: effect of parenteral immunization with vaccines and toxoid.
    Sinha VB; Bhaskaran K
    Bull World Health Organ; 1973; 49(6):605-13. PubMed ID: 4548387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serologic studies of naturally acquired infection with Vibrio cholerae serogroup O1 in the United States.
    Snyder JD; Allegra DT; Levine MM; Craig JP; Feeley JC; DeWitt WE; Blake PA
    J Infect Dis; 1981 Feb; 143(2):182-7. PubMed ID: 7194358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experimental studies on cholera immunization. II. Evidence for protective antitoxic immunity mediated by serum antibodies as well as local antibodies.
    Holmgren J; Andersson A; Wallerstrom G; Ouchterlony O
    Infect Immun; 1972 May; 5(5):662-7. PubMed ID: 4637602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The population composition of cultures of Vibrio cholerae strain 569 B Pakistan in relation to the manufacture of a cholera vaccine (choleragen-anatoxin+O-antigen)].
    Lobanov VV; Nechetskaia RM; Adamova GV
    Zh Mikrobiol Epidemiol Immunobiol; 1988 Aug; (8):73-6. PubMed ID: 2461623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative study of reactions and serological response to cholera vaccines in a controlled field trial conducted in the USSR.
    Burgasov PN; Sumarokov AA; Lelikov VL; Marcuk LM; Fedenev VG; Dzaparidze MN; Karaeva LT; Derteva II
    Bull World Health Organ; 1976; 54(2):163-70. PubMed ID: 798636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toxoid of Clostridium botulinum type F: purification and immunogenicity studies.
    Hatheway CL
    Appl Environ Microbiol; 1976 Feb; 31(2):234-42. PubMed ID: 793522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cholera toxin and toxoid.
    Ungar J; Stanić M; Chariatte N; Varallyay SJ
    Prog Immunobiol Stand; 1971; 5():348-9. PubMed ID: 4660540
    [No Abstract]   [Full Text] [Related]  

  • 39. [Reactogenicity and immunological effectiveness of an oral cholera chemical vaccine in a limited controlled experiment with human revaccination].
    Sumarokov AA; Ivanov NR; Lelikov VL; Dzhaparidze MN; Karaeva LT
    Zh Mikrobiol Epidemiol Immunobiol; 1978; (12):87-92. PubMed ID: 371293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Standardization of chemical cholerogen-toxoid cholera vaccine according to the content of somatic O-antigen].
    Sumarokov AA; Dzhaperidze MN; Ivanov NR; Karaeva LT; Popov AA
    Zh Mikrobiol Epidemiol Immunobiol; 1977 Apr; (4):99-106. PubMed ID: 405829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.